Curatis Holding AG: Initiation of Coverage by valuationLAB

Curatis Holding AG (SIX:CURN) has announced that valuationLAB has initiated coverage and published an equity research report on the company. The report estimates a current risk-adjusted net present value of CHF 20.00 per share, equating to an enterprise value of CHF 103 million.

Before its April 2024 listing on the SIX Swiss Exchange, Curatis had a profitable sales portfolio of over 30 orphan and specialty medicines. These products, including treatments for life-threatening poisoning, were developed over twenty years, securing Curatis a unique position in Switzerland.

Curatis also has a pipeline of advanced projects. Key among these is C-PTBE-01, planned for orphan drug designation filing in the US and EU in the second half of 2024. Licensing agreements and a Phase III trial are slated for 2025, with the drug launch expected in 2027. C-PTBE-01 targets peritumoral brain edema in children with a diffuse midline glioma, showing fewer side effects than current treatments.

The valuationLAB report indicates a substantial increase in company value, with shares valued at CHF 20.00 compared to the current CHF 6.00.